Back to Search
AUDREY SHOEMAKER, MD
MD
Family Medicine Physician
NPI: 1134869985IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
036173131(IL)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF ILLINOIS COLLEGE OF MED (CHI/PEOR/ROCK/CHM-URB)
Class of 2022
Research & Publications (20)
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
PMID 18519752·Clin Cancer Res·2008
7-preclinical
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
PMID 16951189·Cancer Res·2006
7-preclinical
Alleviating perinatal depressive symptoms and stress: a nurse-community health worker randomized trial.
PMID 19551471·Arch Womens Ment Health·2009
2-rct
Steel factor controls primordial germ cell survival and motility from the time of their specification in the allantois, and provides a continuous niche throughout their migration.
PMID 19279135·Development·2009
7-preclinical
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
PMID 19010845·Clin Cancer Res·2008
7-preclinical
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
PMID 18852130·Mol Cancer Ther·2008
7-preclinical
The status of the world's land and marine mammals: diversity, threat, and knowledge.
PMID 18845749·Science·2008
7-preclinical
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
PMID 18841882·J Med Chem·2008
7-preclinical
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
PMID 18451170·Cancer Res·2008
7-preclinical
The distribution and behavior of extragonadal primordial germ cells in Bax mutant mice suggest a novel origin for sacrococcygeal germ cell tumors.
PMID 18415933·Int J Dev Biol·2008
7-preclinical
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
PMID 17256834·J Med Chem·2007
7-preclinical
SyMAP: A system for discovering and viewing syntenic regions of FPC maps.
PMID 16951135·Genome Res·2006
8-other
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
PMID 16899626·Clin Cancer Res·2006
7-preclinical
Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
PMID 16644221·Bioorg Med Chem Lett·2006
7-preclinical
Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
PMID 16603355·Bioorg Med Chem Lett·2006
7-preclinical
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
PMID 16451081·J Med Chem·2006
7-preclinical
Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.
PMID 16331885·Neoplasia·2005
8-other
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.
PMID 16103076·Cancer Res·2005
7-preclinical
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
PMID 15956255·Mol Cancer Ther·2005
7-preclinical
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
PMID 15902208·Nature·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 625 19th St S
Birmingham, AL 35233 - Phone
- (205) 934-1111
Quick Facts
- NPI
- 1134869985
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile